Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B

mBio

Volumn 5, Issue 6, 2014, Pages

  Vieira, Valdimara C ^a,b   Leonard, Brandon ^a   White, Elizabeth A ^c   Starrett, Gabriel J ^a   Temiz, Nuri A ^a   Lorenz, Laurel D ^d   Lee, Denis ^d   Soares, Marcelo A ^b,e   Lambert, Paul F ^d   Howley, Peter M ^c   Harris, Reuben S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

APOBEC3B ENZYME; DEAMINASE; GENOMIC DNA; MESSENGER RNA; ONCOPROTEIN; PROTEIN E6; PROTEIN P53; UNCLASSIFIED DRUG; APOBEC3B PROTEIN, HUMAN; CYTIDINE DEAMINASE; DNA BINDING PROTEIN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; REPRESSOR PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; ENZYME ACTIVITY; GENE INACTIVATION; GENETIC TRANSCRIPTION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; INNATE IMMUNITY; LUNG CANCER; MUTAGENESIS; NONHUMAN; OVARY CANCER; PAPILLOMAVIRUS INFECTION; PHENOTYPE; SOMATIC MUTATION; UPREGULATION; UTERINE CERVIX CANCER; VIRUS GENOME; WART VIRUS; BIOSYNTHESIS; CELL CULTURE; ENZYMOLOGY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HOST PATHOGEN INTERACTION; KERATINOCYTE; METABOLISM; MUTATION; PAPILLOMAVIRIDAE; PHYSIOLOGY; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

CELLS, CULTURED; CYTIDINE DEAMINASE; DNA-BINDING PROTEINS; HOST-PATHOGEN INTERACTIONS; HUMANS; KERATINOCYTES; MUTATION; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; REPRESSOR PROTEINS; TRANSDUCTION, GENETIC; TRANSFECTION; UP-REGULATION;

EID: 84920969941     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.02234-14     Document Type: Article

References (60)

1. Harris RS, Hultquist JF, Evans DT. 2012. The restriction factors of human immunodeficiency virus. J. Biol. Chem. 287:40875-40883. http://dx.doi.org/10.1074/jbc.R112.416925.
2. Malim MH, Bieniasz PD. 2012. HIV restriction factors and mechanisms of evasion. Cold Spring Harb. Perspect. Med. 2:a006940. http://dx.doi.org/10.1101/cshperspect.a006940.
3. Refsland EW, Harris RS. 2013. The APOBEC3 family of retroelement restriction factors. Curr. Top. Microbiol. Immunol. 371:1-25. http://dx.doi.org/10.1007/978-3-642-37765-5_1.
4. Di Noia JM, Neuberger MS. 2007. Molecular mechanisms of antibody somatic hypermutation. Annu. Rev. Biochem. 76:1-22. http://dx.doi.org/10.1146/annurev.biochem.76.061705.090740.
5. Conticello SG. 2008. The AID/APOBEC family of nucleic acid mutators. Genome Biol. 9:229. http://dx.doi.org/10.1186/gb-2008-9-7-229.
6. Harris RS, Petersen-Mahrt SK, Neuberger MS. 2002. RNA editing enzyme APOBEC1 and some of its homologs can act asDNAmutators. Mol. Cell 10:1247-1253. http://dx.doi.org/10.1016/S1097-2765(02)00742-6.
7. Petersen-Mahrt SK, Neuberger MS. 2003. In vitro deamination of cytosine to uracil in single-stranded DNA by apolipoprotein B editing complex catalytic subunit 1 (APOBEC1). J. Biol. Chem. 278:19583-19586. http://dx.doi.org/10.1074/jbc.C300114200.
8. Severi F, Chicca A, Conticello SG. 2011. Analysis of reptilian APOBEC1 suggests that RNA editing may not be its ancestral function. Mol. Biol. Evol. 28:1125-1129. http://dx.doi.org/10.1093/molbev/msq338.
9. Turelli P, Mangeat B, Jost S, Vianin S, Trono D. 2004. Inhibition of hepatitis B virus replication by APOBEC3G. Science 303:1829. http://dx.doi.org/10.1126/science.1092066.
10. Chen H, Lilley CE, Yu Q, Lee DV, Chou J. 2006. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr. Biol. 16: 480-485. http://dx.doi.org/10.1016/j.cub.2006.01.031.
11. Vartanian JP, Guétard D, Henry M, Wain-Hobson S. 2008. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 320:230-233. http://dx.doi.org/10.1126/science.1153201.
12. Suspène R, Aynaud MM, Koch S, Pasdeloup D, Labetoulle M, Gaertner B, Vartanian JP, Meyerhans A, Wain-Hobson S. 2011. Genetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivo. J. Virol. 85: 7594-7602. http://dx.doi.org/10.1128/JVI.00290-11.
13. Ooms M, Krikoni A, Kress AK, Simon V, Münk C. 2012. APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1. J. Virol. 86:6097-6108. http://dx.doi.org/10.1128/JVI.06570-11.
14. Vieira VC, Soares MA. 2013. The role of cytidine deaminases on innate immune responses against human viral infections. Biomed. Res. Int. 2013: 1-18. http://dx.doi.org/10.1155/2013/683095.
15. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. 2012. The biology and life-cycle of human papillomaviruses. Vaccine 30:F55-F70. http://dx.doi.org/10.1016/j.vaccine.2012.06.083.
16. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. 2010. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401:70-79. http://dx.doi.org/10.1016/j.virol.2010.02.002.
17. De Villiers EM. 2013. Cross-roads in the classification of papillomaviruses. Virology 445:2-10. http://dx.doi.org/10.1016/j.virol.2013.04.023.
18. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518-527. http://dx.doi.org/10.1056/NEJMoa021641.
19. Zur Hausen H. 2009. Papillomaviruses in the causation of human cancers-a brief historical account. Virology 384:260-265. http://dx.doi.org/10.1016/j.virol.2008.11.046.
20. D’Souza G, Dempsey A. 2011. The role of HPV in head and neck cancer and review of the HPV vaccine. Prev. Med. 53:S5-S11. http://dx.doi.org/10.1016/j.ypmed.2011.08.001.
21. Zur Hausen H. 2002. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2:342-350. http://dx.doi.org/10.1038/nrc798.
22. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, zur Hausen H. 1985. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314:111-114. http://dx.doi.org/10.1038/314111a0.
23. Münger K, Phelps WC, Bubb V, Howley PM, Schlegel R. 1989. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63:4417-4421.
24. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. 1989. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 8:3905-3910.
25. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136. http://dx.doi.org/10.1016/0092-8674(90)90409-8.
26. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505. http://dx.doi.org/10.1016/0092-8674(93)90384-3.
27. Münger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. 1989. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8:4099-4105.
28. Dyson N, Howley PM, Münger K, Harlow E. 1989. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-937. http://dx.doi.org/10.1126/science.2537532.
29. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, Yee D, Temiz NA, Donohue DE, McDougle RM, Brown WL, Law EK, Harris RS. 2013. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494:366-370. http://dx.doi.org/10.1038/nature11881.
30. Burns MB, Temiz NA, Harris RS. 2013. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet. 45:1-8. http://dx.doi.org/10.1038/ng.2701.
31. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL, Saksena G, Harris S, Shah RR, Resnick MA, Getz G, Gordenin DA. 2013. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45:1-8. http://dx.doi.org/10.1038/ng.2702.
32. Leonard B, Hart SN, Burns MB, Carpenter MA, Temiz NA, Rathore A, Vogel RI, Nikas JB, Law EK, Brown WL, Li Y, Zhang Y, Maurer MJ, Oberg AL, Cunningham JM, Shridhar V, Bell DA, April C, Bentley D, Bibikova M, Cheetham RK, Fan JB, Grocock R, Humphray S, Kingsbury Z, Peden J, Chien J, Swisher EM, Hartmann LC, Kalli KR, Goode EL, Sicotte H, Kaufmann SH, Harris RS. 2013. APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res. 73:7222-7231. http://dx.doi.org/10.1158/0008-5472.CAN-13-1753.
33. Taylor BJ, Nik-Zainal S, Wu YL, Stebbings LA, Raine K, Campbell PJ, Rada C, Stratton MR, Neuberger MS. 2013. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. eLife 2:e00534. http://dx.doi.org/10.7554/eLife.00534.
34. Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR. 2014. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep. 7:1833-1841. http://dx.doi.org/10.1016/j.celrep.2014.05.012.
35. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, Menzies A, Martin S, Leung K, Chen L, Leroy C, Ramakrishna M, Rance R, Lau KW, Mudie LJ, Varela I, McBride DJ, Bignell GR, Cooke SL, Shlien A, Gamble J, Whitmore I, Maddison M, Tarpey PS, Davies HR, Papaemmanuil E, Stephens PJ, McLaren S, Butler AP, Teague JW, Jönsson G, Garber JE, Silver D, Miron P, Fatima A, Boyault S, Langerød A, Tutt A, Martens JWM, Aparicio SA, Borg Å, Salomon AV, Thomas G, Børresen-Dale AL, Richardson AL, Neuberger MS, Futreal PA, Campbell PJ, Stratton MR, Cancer, Breast Working Group of the International Cancer Genome Consortium. 2012. Mutational processes molding the genomes of 21 breast cancers. Cell 149:979-993. http://dx.doi.org/10.1016/j.cell.2012.04.024.
36. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jäger N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt ANJ, Valdés-Mas R, van Buuren MM, van’t Veer L, Vincent-Salomon A, Waddell N, Yates LR, Australian Pancreatic Cancer Genome Initiative, ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, ICGC PedBrain, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR. 2013. Signatures of mutational processes in human cancer. Nature 500:415-421. http://dx.doi.org/10.1038/nature12477.
37. Shinohara M, Io K, Shindo K, Matsui M, Sakamoto T, Tada K, Kobayashi M, Kadowaki N, Takaori-Kondo A. 2012. APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci. Rep. 2:806. http://dx.doi.org/10.1038/srep00806.
38. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS. 2010. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38:4274-4284. http://dx.doi.org/10.1093/nar/gkq174.
39. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, Brown WL, Harris RS. 2011. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85:11220-11234. http://dx.doi.org/10.1128/JVI.05238-11.
40. Refsland EW, Hultquist JF, Harris RS. 2012. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog. 8:e1002800. http://dx.doi.org/10.1371/journal.ppat.1002800.
41. Lorenz LD, Rivera Cardona J, Lambert PF. 2013. Inactivation of p53 rescues the maintenance of high risk HPV DNA genomes deficient in expression of E6. PLoS Pathog. 9:e1003717. http://dx.doi.org/10.1371/journal.ppat.1003717.
42. White EA, Kramer RE, Tan MJ, Hayes SD, Harper JW, Howley PM. 2012. Comprehensive analysis of host cellular interactions with human papillomavirus E6 proteins identifies new E6 binding partners and reflects viral diversity. J. Virol. 86:13174-13186. http://dx.doi.org/10.1128/JVI.02172-12.
43. White EA, Walther J, Javanbakht H, Howley PM. 2014. Genus beta human papillomavirus E6 proteins vary in their effects on the transactivation of p53 target genes. J. Virol. 88:8201-8212. http://dx.doi.org/10.1128/JVI.01197-14.
44. Chrisofos M, Skolarikos A, Lazaris A, Bogris S, Deliveliotis CH. 2004. HPV 16/18-associated condyloma acuminatum of the urinary bladder: first international report and review of literature. Int. J. STD AIDS 15: 836-838. http://dx.doi.org/10.1258/0956462042563783.
45. Lee SS, Weiss RS, Javier RT. 1997. Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. U. S. A. 94:6670-6675. http://dx.doi.org/10.1073/pnas.94.13.6670.
46. Kiyono T, Hiraiwa A, Fujita M, Hayashi Y, Akiyama T, Ishibashi M. 1997. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. U. S. A. 94:11612-11616. http://dx.doi.org/10.1073/pnas.94.21.11612.
47. Javier RT. 2008. Cell polarity proteins: common targets for tumorigenic human viruses. Oncogene 27:7031-7046. http://dx.doi.org/10.1038/onc.2008.352.
48. Nagasaka K, Kawana K, Osuga Y, Fujii T. 2013. PDZ domains and viral infection: versatile potentials of HPV-PDZ interactions in relation to malignancy. Biomed. Res. Int. 2013:369712. http://dx.doi.org/10.1155/2013/369712.
49. Dürst M, Gallahan D, Jay G, Rhim JS. 1989. Glucocorticoid-enhanced neoplastic transformation of human keratinocytes by human papillomavirus type 16 and an activated ras oncogene. Virology 173:767-771. http://dx.doi.org/10.1016/0042-6822(89)90595-3.
50. Pei XF, Meck JM, Greenhalgh D, Schlegel R. 1993. Cotransfection of HPV-18 and v-fos DNA induces tumorigenicity of primary human keratinocytes. Virology 196:855-860. http://dx.doi.org/10.1006/viro.1993.1546.
51. Crook T, Storey A, Almond N, Osborn K, Crawford L. 1988. Human papillomavirus type 16 cooperates with activated ras and fos oncogenes in the hormone-dependent transformation of primary mouse cells. Proc. Natl. Acad. Sci. U. S. A. 85:8820-8824. http://dx.doi.org/10.1073/pnas.85.23.8820.
52. Münger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M, Huh K. 2004. Mechanisms of human papillomavirusinduced oncogenesis. J. Virol. 78:11451-11460. http://dx.doi.org/10.1128/JVI.78.21.11451-11460.2004.
53. Wang Z, Wakae K, Kitamura K, Aoyama S, Liu G, Koura M, Monjurul AM, Kukimoto I, Muramatsu M. 2014. APOBEC3 deaminases induce hypermutation in human papillomavirus 16 DNA upon beta interferon stimulation. J. Virol. 88:1308-1317. http://dx.doi.org/10.1128/JVI.03091-13.
54. Allen-Hoffmann BL, Schlosser SJ, Ivarie CA, Sattler CA, Meisner LF, Connor SL. 2000. Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS. J. Invest. Dermatol. 114:444-455. http://dx.doi.org/10.1046/j.1523-1747.2000.00869.x.
55. Todaro GJ, Green H. 1963. Quantitative studies of the growth of mouse embryo cells in culture and their development into established cell lines. J. Cell Biol. 17:299-313. http://dx.doi.org/10.1083/jcb.17.2.299.
56. Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA, Louis DN, Li FP, Rheinwald JG. 2000. Human keratinocytes that express hTERT and also bypass a p16(INK4_)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol. Cell. Biol. 20:1436-1447. http://dx.doi.org/10.1128/MCB.20.4.1436-1447.2000.
57. Wei W, Barron PD, Rheinwald JG. 2010. Modulation of TGF-_-inducible hypermotility by EGF and other factors in human prostate epithelial cells and keratinocytes. In Vitro Cell. Dev. Biol. Anim. 46:841-855. http://dx.doi.org/10.1007/s11626-010-9353-8.
58. Degen M, Natarajan E, Barron P, Widlund HR, Rheinwald JG. 2012. MAPK/ERK-dependent translation factor hyperactivation and dysregulated laminin _2 expression in oral dysplasia and squamous cell carcinoma. Am. J. Pathol. 180:2462-2478. http://dx.doi.org/10.1016/j.ajpath.2012.02.028.
59. Smith JA, White EA, Sowa ME, Powell ML, Ottinger M, Harper JW, Howley PM. 2010. Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. Proc. Natl. Acad. Sci. U. S. A. 107:3752-3757. http://dx.doi.org/10.1073/pnas.0914818107.
60. Broad Institute, TCGA Genome Data Analysis Center. 2013. Mutation analysis (MutSigCV v0.9). Broad Institute of MIT and Harvard, Cambridge, MA.